The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: BioExx Specialty Proteins

Monday Deal Review: October 14, 2013

  Welcome to your Monday Biotech Deal Review for October 14, 2013!

Of particular note this week is the innovative collaboration between Sirona Biochem and Bloom Burton & Co. The venture seeks to develop and commercialize new therapeutics in the areas of inflammation and infectious disease. Such an arrangement purports to take advantage of Sirona’s proprietary fluorination technology platform, and Bloom Burton’s knowledge of the market and expertise in commercialization, delivering to market products targeted towards rare or neglected inflammatory diseases and bacterial resistance. This model shows significant promise, so look to this space to see how the relationship progresses.

Hit the break to get the full scoop on the week’s major stories!

Read more of this post

Monday Deal Review: October 7, 2013

  Welcome to your Monday Biotech Deal Review for October 7, 2013! A busy week saw significant activity in both the financing and commercial agreement spaces.  Of note is MedMira recieving a $6.1 million equity investment.

Hit the break for the full rundown of the week’s major biotech news! And thanks again to Jennifer Ng of Norton Rose Fulbright for helping out with this week’s post.

Read more of this post

Monday Deal Review: September 30, 2013

  Welcome to your Monday Biotech Deal Review for September 30, 2013! There has been a lot of activity in the M&A and finanicngs space the last week.  Hit the break for the full rundown of the weeks’s major biotech news!

Read more of this post

Monday Deal Review: November 26, 2012

Welcome to your Monday Biotech Deal Review for November 26, 2012. This past week saw Valeant continue their aggressive stock repurchase program. Valeant plans to repurchase up to $1.5 billion worth of its own stock, senior notes or debt. Further, we saw Paladin expand its potential sales reach with the purchase of a controlling stake in Mexico-based Ativa Pharma.  Get the full breakdown of these and many more of the past week’s major biotech stories.   
Read more of this post

Monday Biotech Deal Review: July 9, 2012

Welcome to your Monday Biotech Deal Review for July 9, 2012.  Highlights from the previous two weeks include the announcement of a $13.25 million prospectus offering by Trimel Pharmaceuticals, and the announcement of a $200 million exchange offer by Angiotech on its Senior Floating Rate Notes due 2013.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: June 11, 2012

Welcome to your Monday Biotech Deal Review for June 11, 2012.  The Monday Biotech Deal Review is back with Norton Rose Canada summer law student Jennifer Ng, who has agreed to assist with the deal review over the summer months.  A very warm thanks to Keldeagh Lindsay for his dedication and contribution to the blog!  The below covers transactions in the biotech space since since May 14, 2012.  Highlights include the closing of the first tranche of Stellar Pharmaceuticals’ debt financing, as well as private placements each worth approximately $6 million closed for each of MedMira Inc. and Lorus Therapeutics.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: July 11, 2011

Welcome to your Monday Biotech Deal Review for July 11, 2011.  This week is a double feature, owing to last week’s break due to both Canada Day and Fourth of July holidays.  There was a lot of activity over the past two weeks in the biotech space.   Read on to catch up!  Read more of this post

Monday Biotech Deal Review: June 13, 2011

Welcome to your Monday Biotech Deal Review for June 13, 2011.  Notable stories include the completion of GeneNews’ early warrant exercise program and debenture conversion opportunity, resulting in gross proceeds of nearly $3M to the Company.  As well, Somaxon and Paladin Labs have teamed up for the commercialization of Selinor in Canada, South America and Africa.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: February 28, 2011

Welcome to your Monday biotech deal review for February 28, 2011.  In addition to the usual reviews of biotech corporate activity, this week featured the announcement of Theratechnologies’ U.S. IPO, the closing of a $40M bought deal by Paladin Labs, Angiotech’s recapitalization amendment and the appointment of a Receiver for LAB Research.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: April 5, 2010

The past week was consumed with religious holidays and summer weather, and also with year-end earnings announcements, so there was less deal activity than usual.  Still, there’s about $500 million of goodies to check out after the jump, thanks mostly to MDS and its delightful Dutch auction. Read more of this post

Monday Biotech Deal Review: March 22, 2010

Bought deals are all the rage this week, with BioExx and Osta Biotechnologies both heading in that direction.  Also, everywhere we look, warrants are being exercised and debentures are being converted. We even noted the green shoots of a new Canadian listed biotech company poking through the ground via a CPC transaction.  Is there a Spring thaw in Canada’s biotech capital markets?  Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 129 other followers